Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
“We continue our commercial preparation in the UK and in parallel are working closely with the Medicines and Healthcare products Regulatory Agency (MHRA) to address regulatory requirements for a potential Conditional Marketing Authorization. With its global reach, PCI will provide a critical function in the supply chain, by directly purchasing lenzilumab for further distribution in the UK and facilitating this key process for Humanigen,” said Edward Jordan, Chief Commercial Officer. “It is anticipated that we will complete our response to MHRA soon after the top-line results from the ACTIV-5/BET-B clinical trial with lenzilumab are received.”
If authorized, lenzilumab will offer an important treatment option to patients hospitalized with COVID-19. Hospitalizations from COVID-19 continue in the United Kingdom with more than 235,000 admitted year-to-date and with ~5,000 currently hospitalized.1 In addition, Humanigen believes that treatment with lenzilumab may deliver economic value to the healthcare system. Previously published research has demonstrated that treatment with lenzilumab may save the National Health Service over £10,000 per patient.2
Lenzilumab is an investigational product and is not approved or authorized in any country.
Lenzilumab is a proprietary Humaneered® first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome, or cytokine storm, associated with COVID-19 and other indications. Lenzilumab binds to and neutralizes GM-CSF, potentially improving outcomes for patients hospitalized with COVID-19. Humanigen believes that GM-CSF neutralization with lenzilumab also has the potential to reduce the hyperinflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD).
In CAR-T, lenzilumab successfully achieved the pre-specified primary endpoint at the recommended dose in a Phase 1b study with Yescarta® in which the overall response rate was 100% and no patient experienced severe cytokine release syndrome or severe neurotoxicity. Based on these results, Humanigen plans to test lenzilumab in a randomized, multicenter, potentially registrational, Phase 3 study (“SHIELD”) to evaluate its efficacy and safety when combined with Yescarta and Tecartus® CAR-T therapies in non-Hodgkin lymphoma. Lenzilumab will also be tested to assess its ability to prevent and/or treat aGvHD in patients undergoing allogeneic hematopoietic stem cell transplantation.
A study of lenzilumab is also underway for patients with chronic myelomonocytic leukemia (CMML) exhibiting RAS pathway mutations. This study builds on evidence from a Phase 1 study, conducted by Humanigen, that showed RAS mutations are associated with hyper-proliferative features, which may be sensitive to GM-CSF neutralization.
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany, and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding the potential clinical and UK healthcare economic benefits of lenzilumab, statements pertaining to the sufficiency of results from ACTIV-5/BET-B to support further progress in respect of Humanigen’s pursuit of Conditional Marketing Authorization in the UK; statements regarding the SHIELD, aGvHD, and CMML studies, and other statements regarding the potential for lenzilumab to improve the safety and efficacy of CAR-T and our plans relating to lenzilumab.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation or arbitration involving the company; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the SEC.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.
- UK Health Security Agency. (2022, June 15). Healthcare in United Kingdom. GOV.UK Coronavirus (COVID-19) in the UK. Retrieved June 15, 2022, from https://coronavirus.data.gov.uk/details/healthcare
- Kilcoyne, A. et al. (2022). Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with coronavirus disease 19 (COVID-19) from the perspective of National Health Service England. ClinicoEconomics and Outcomes Research. https://doi.org/10.2147/CEOR.S360741
Humaneered® is a trademark of Humanigen, Inc.
Yescarta® and Tecartus® are trademarks of Gilead Sciences, Inc., or its related companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Humanigen Investor Relations
PCI Pharma Services Contact
Ty Guzman-Touchberry, WE Communications
email@example.com / +1-212-551-4877
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venerable MMORPG Mabinogi Enters The Great Era Of Commerce With The First Of Two Summer Game Updates30.6.2022 23:20:00 EEST | Press release
Mabinogi , Nexon’s free-to-play fantasy MMORPG, announced gigantic two-part summer updates today, the first of which concentrates on the expansion of player Commerce, including upgrades to trading and bartering systems, new ports, plus entirely new merchant areas available in Iria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005876/en/ Nexon America's Mabinogi "Great Era of Commerce" (Graphic: Business Wire) In order to give Mabinogi’s world of Erinn a more connected, energetic feel, ports have been reborn and a trade union was created featuring large ships to get players to their destinations faster. Build your merchant empire thanks to a brand new trade shop in Iria selling limited time items, and beneficial trade system changes that expand the Trading life skill with a host of economic additions. Rentable transportation, in the form of camels and dog sleds, are now available to be used for player trade runs. Play
Verisign Reports Internet Has 350.5 Million Domain Name Registrations at the End of the First Quarter of 202230.6.2022 23:06:00 EEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the first quarter of 2022 closed with 350.5 million domain name registrations across all top-level domains, an increase of 8.8 million domain name registrations, or 2.6%, compared to the fourth quarter of 2021.1,2 Domain name registrations have increased by 13.2 million, or 3.9%, year over year.1,2 The .com and .net TLDs had a combined total of 174.7 million domain name registrations in the domain name base3 at the end of the first quarter of 2022, an increase of 1.2 million domain name registrations, or 0.7%, compared to the fourth quarter of 2021. The .com and .net TLDs had a combined increase of 6.7 million domain name registrations, or 4.0%, year over year. As of March 31, 2022, the .com domain name base totaled 161.3 million domain name registrations, and the .net domain name base totaled 13.4 million domain name registrations. New .com and .net domai
Spinal Cord Stimulation Delivers Improved Arm Function30.6.2022 18:30:00 EEST | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces a Nature Neuroscience publication showing the potential for ONWARD’s ARCIM Therapy to restore movement and function in hands and arms after spinal cord injury. Regaining hand and arm function is the highest priority for many people with cervical spinal cord injury. Even mild functional deficits in hand and arm function lead to significantly reduced independence and quality of life. It has historically been challenging to develop new therapies for hand and arm function because their movements are complex and multidimensional. Researchers in today’s Nature Neuroscience publication investigated a potentially more effective approach to improving motor control of the upper limbs after spinal cord injury – an implantable neurostimulation system that modulates the spinal cord region involved in contr
NelsonHall Highlights the Strength of Mercans’ Global Employer of Record Services30.6.2022 17:00:00 EEST | Press release
“We are delighted that NelsonHall, the leading global analyst firm, has recognized Mercans as one of the fastest growing technology-driven global employer of record service providers. NelsonHall’s analyst report is a testament to the success of our EOR service line and demonstrates that our proprietary technology, combined with Mercans’ local presence in 160 countries, creates value for our customers and their employees,” said Tatjana Domovits, Group CEO of Mercans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005419/en/ Salman Saeed - Head of EOR - Mercans (Photo: AETOSWire) Mercans’ global employer of record services delivery model is unique in the industry and focuses on the excellence in customer and employee experience through digitalization, employee-centric support, and in-country expertise. Mercans has invested significantly in developing a proprietary global payroll software, HR Blizz™ with 160 country cover
IBS Intelligence Recognizes Temenos as the #1 Best-Selling Banking Software in Six Categories; the Highest Awarded to Any Technology Provider30.6.2022 16:42:00 EEST | Press release
Temenos (SIX: TEMN) has been recognized as the market's leading open platform for composable banking in the IBS Intelligence Sales League Table (SLT). IBSi recognized Temenos as the leader in six categories, more than any other technology provider, including digital banking and channels, core banking and payments. The IBSi SLT 2022 assessed systems purchases made by over 1000+ banks across 250+ products from 60 suppliers. Temenos was ranked: #1 best-selling Universal Banking - Core Banking solution with 49 new named deals, maintaining its market leadership with 49% of total deals in the market. Temenos was the only major core vendor to increase its market share year-on-year #1 for Digital Banking and Channels – signing 79 deals, maintaining more than 50% market share in the Americas #1 in Payments Systems for retail banking, for the fourth consecutive year, with 43 new named deals #1 for Risk Management with 39 new name deals, 2X the number of deals of the next vendor #1 for Islamic Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom